Skip to main content Skip to search Skip to main navigation

FDA: Revised Q&A on Biosimilar Development

On 17 September 2021, the US FDA released the revised Q&A Guidance on Biosimilar Development and the BPCI Act. The 28-page document provides rapid, development-related guidance to biosimilar and interchangeable biosimilar sponsors and other stakeholders on discrete issues.

The Rev2-document includes newly finalised Q&As on the submission of a supplement to an approved application for a biosimilar. This covers the nature and type of information a sponsor should provide to support a post-approval manufacturing change for a licensed biosimilar or interchangeable biosimilar.

Out of the ordinary and parallel to the revised Q&A (Rev2), the FDA has already released a draft of the upcoming Revision3 document. Therein, solely Question I.12 of the in 2018 released original version, which is missing in the current Rev2, is retained. It addresses how an applicant can demonstrate that its proposed injectable biosimilar product or proposed injectable interchangeable biosimilar product has the same “strength” as the reference product. The draft guidance does not include any other new Q&As or changes. The draft is currently open for comments.

These Q&A guidance documents are part of a series of guidance documents that FDA has developed to facilitate development of biosimilar and interchangeable biosimilar products and they are another step we’re taking to provide increased regulatory certainty and predictability for stakeholders.


Source:
FDA: Newly added guidance documents

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next